ArticleBritish journal of cancer2009
Expression of endoglin (CD105) in cervical cancer.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- ¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.European journal of nuclear medicine and molecular imaging · 2011Trial
- Cancer-Associated Fibroblasts: Clinical Applications in Imaging and Therapy.Tomography (Ann Arbor, Mich.) · 2025Review
- Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer.Frontiers in oncology · 2021Article
- Prognostic value of microvessel density in cervical cancer.Cancer cell international · 2018Review
- Modulatory Effects of Chemoradiation on Angiogenic Factors and Laminin in Cervical Cancer: Link with Treatment ResponseAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.Oncogene · 2016Article
- Tumor neoangiogenesis detection by confocal laser endomicroscopy and anti-CD105 antibody: Pilot study.World journal of gastrointestinal oncology · 2015Article
- Article
- Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer.Molecular cancer · 2015Article
- Elderberries: a source of ribosome-inactivating proteins with lectin activity.Molecules (Basel, Switzerland) · 2015Review
- Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.Gynecologic oncology research and practice · 2015Review
- Angiogenesis and antiangiogenic agents in cervical cancer.OncoTargets and therapy · 2014Review
- Intravascular papillary endothelial hyperplasia: histomorphological and immunohistochemical features.Diagnostic pathology · 2013Article
- CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma.Acta neuropathologica · 2012Article
- Endoglin - a marker of vascular endothelial cell proliferation in cancer.Contemporary oncology (Poznan, Poland) · 2012Article
- Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- Review
- Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors.World journal of gastroenterology · 2011Article
- Endoglin-targeted cancer therapy.Current drug delivery · 2011Review
- Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer.Experimental and therapeutic medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we have investigated the role of endoglin (CD105), a regulator of transforming growth factor (TGF)-beta(1) signalling on endothelial cells, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor-A (VEGF-A) in cervical cancer. We have measured the number and determined the location of both newly formed (CD105-positive) and the overall number of (CD31-positive) blood vessels, and bFGF and VEGF-A expression using immunohistochemistry in 30 cervical carcinoma specimens. Vascular endothelial growth factor-A mRNA expression was determined using RNA-in situ hybridisation. CD105- and CD31-positive vessels and bFGF- and VEGF-A-positive cells were predominantly present in the stroma. The presence of CD105- and CD31-positive vessels in the stroma did neither correlate with the number of VEGF-A-positive cells nor the number of bFGF-positive cells. However, the number of CD105- and CD31-positive vessels was associated with the expression of VEGF-A mRNA in the epithelial cell clusters (P=0.013 and P=0.005, respectively). The presence of CD105-positive and CD31-positive vessels was associated with the expression of alphavbeta6 (a TGF-beta(1) activator; P=0.013 and P=0.006, respectively). Clinically, the number of CD105-positive vessels associated with the number of lymph node metastasis (P<0.001). Furthermore, the presence of CD105-positive vessels within the epithelial cell clusters associated with poor disease-free survival (P=0.007).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.